Cardiovascular Journal of Africa: Vol 29 No 5 (September/October 2018)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 5, September/October 2018

328

AFRICA

43. Rowland CM, Pullinger CR, Luke MM, Shiffman D, Green L,

Movsesyan I,

et al

. Lipoprotein (a), LPA Ile4399Met, and fibrin clot

properties.

Thromb Res

2014;

133

(5): 863–867. doi: 10.1016/j.throm-

res.2014.01.024.

44. McDermott MM, Lloyd-Jones DM. The role of biomarkers and genet-

ics in peripheral arterial disease.

J Am Coll Cardiol

2009;

: 1228–1237.

doi: 10.1016/j.jacc.2009.04.081.

45. McDermott MM, Ferrucci L, Guralnik JM, Tian L, Green D, Liu K,

. Elevated levels of inflammation, d-dimer, and homocysteine are asso-

ciated with adverse calf muscle characteristics and reduced calf strength

in peripheral arterial disease.

J Am Coll Cardiol

2007;

: 897–905. doi:

10.1016/j.jacc.2007.05.017.

46. MacEwan DJ. TNF receptor subtype signalling: differences and cellu-

lar consequences.

Cell Signal

2002;

: 477–492. doi: 10.1016/S0898-

6568(01)00262-5.

47. Komosinska-Vassev K, Olczyk P, Winsz-Szczotka K, Klimek K, Olczyk

K. Age- and gender-dependent changes in circulating concentrations of

tumor necrosis factor-alpha, soluble tumor necrosis factor receptor-1

and sulfated glycosaminoglycan in healthy people.

Clin Chem Lab Med

2011;

: 121–127. doi: 10.1515/cclm.2011.007.

48. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi

et al.

High circulating levels of cytokines (IL-6 and TNFalpha), adhe-

sion molecules (VCAM-1 and ICAM-1) and selectins in patients with

peripheral arterial disease at rest and after a treadmill test.

Vasc Med

2003;

: 15–19. doi: 10.1191/1358863x03vm466oa.

49. Botti C, Maione C, Dogliotti G, Russo P, Signoriello G, Molinari AM,

et al

. Circulating cytokines present in the serum of peripheral arterial

disease patients induce endothelial dysfunction.

J Biol Regul Homeost

Agents

2012;

: 67–79. doi:

50. Gardner AW, Parker DE, Montgomery PS, Sosnowska D, Casanegra

AI, Esponda OL,

et al

. Impaired vascular endothelial growth factor A

and inflammation in patients with peripheral artery disease.

Angiology

2014;

: 683–690. doi: 10.1177/0003319713501376.

51. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: selec-

tins and integrins.

Crit Rev Immunol

1999;

: 389–429. doi: 10.1615/

CritRevImmunol.v19.i5-6.20.

52. Cheng CH, Chen YS, Shu KH, Chang HR, Chou MC. Higher serum

levels of soluble intracellular cell adhesion molecule-1 and soluble

vascular cell adhesion molecule predict peripheral artery disease in

haemodialysis patients.

Nephrology

(Carlton) 2012;

: 718–724. doi:

10.1111/j.1440-1797.2012.01654.x.

53. Signorelli SS, Anzaldi M, Fiore V, Simili M, Puccia G, Libra M,

et al

Patients with unrecognized peripheral arterial disease (PAD) assessed by

ankle-brachial index (ABI) present a defined profile of proinflammatory

markers compared to healthy subjects.

Cytokine

2012;

: 294–298. doi:

10.1016/j.cyto.2012.04.038.

54. McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Green

et al.

Circulating blood markers and functional impairment in

peripheral arterial disease.

J Am Geriatr Soc

2008;

: 1504–1510. doi:

10.1111/j.1532-5415.2008.01797.x.

55. Glowinska-Olszewska B, Tolwinska J, Urban M. Relationship between

endothelial dysfunction, carotid artery intima media thickness and

circulating markers of vascular inflammation in obese hypertensive chil-

dren and adolescents.

J Pediatr Endocrinol Metab

2007;

: 1125–1136.

doi: 10.1515/JPEM.2007.20.10.1125.

56. Eikendal AL, Evelein AM, Uiterwaal CS, van der Ent CK, Visseren FL,

Bots ML,

et al

. Relation between circulating inflammatory chemokines

and vascular characteristics in healthy, young children.

J Am Heart

Assoc

2015;

: e002346. doi: 10.1161/jaha.115.002346.

57. Forstermann U, Xia N, Li H. Roles of vascular oxidative stress and

nitric oxide in the pathogenesis of atherosclerosis.

Circ Res

2017;

120

713–735. doi: 10.1161/CIRCRESAHA.116.309326.

58. Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology

and potential biomarkers for peripheral artery disease.

Int J Mol Sci

2015;

: 11294–11322. doi: 10.3390/ijms160511294.

59. Pipinos, II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM,

et al

. Mitochondrial defects and oxidative damage in patients with

peripheral arterial disease.

Free Radic Biol Med

2006;

: 262–269. doi:

10.1016/j.freeradbiomed.2006.04.003.

60. Kals J, Kampus P, Kals M, Pulges A, Teesalu R, Zilmer K,

et al

Inflammation and oxidative stress are associated differently with

endothelial function and arterial stiffness in healthy subjects and in

patients with atherosclerosis.

Scand J Clin Lab Invest

2008;

: 594–601.

doi: 10.1080/00365510801930626.

61. Loffredo L, Pignatelli P, Cangemi R, Andreozzi P, Panico MA, Meloni

et al.

Imbalance between nitric oxide generation and oxidative stress

in patients with peripheral arterial disease: effect of an antioxidant

treatment.

J Vasc Surg

2006;

: 525–530. doi: 10.1016/j.jvs.2006.05.023.

62. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo

et al.

NOX2 up-regulation is associated with artery dysfunction in

patients with peripheral artery disease.

Int J Cardiol

2013;

165

: 184–192.

doi: 10.1016/j.ijcard.2012.01.069.

63. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated

reactive nitrogen species convert LDL into an atherogenic form

in vitro.

J Clin Invest

1999;

103

: 1547–1560. doi: 10.1172/JCI5549.

64. Ali Z, Sarcia P, Mosley TH Jr, Kondragunta V, Kullo IJ. Association

of serum myeloperoxidase with the ankle-brachial index and

peripheral arterial disease.

Vasc Med

2009;

: 215–220. doi:

10.1177/1358863X08101999.

65. Haslacher H, Perkmann T, Gruenewald J, Exner M, Endler G,

Scheichenberger V,

et al

. Plasma myeloperoxidase level and peripheral

arterial disease

. Eur J Clin Invest

2012;

: 463–469. doi: 10.1111/j.1365-

2362.2011.02601.x.

66. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin

A, Burillo E, Zalba G,

et al.

Galectin-3, a biomarker linking oxida-

tive stress and inflammation with the clinical outcomes of patients

with atherothrombosis.

J Am Heart Assoc

2014;

. doi: 10.1161/

JAHA.114.000785.

67. Zumrutdal A, Sezer S, Demircan S, Seydaoglu G, Ozdemir FN, Haberal

M. Cardiac troponin I and beta 2 microglobulin as risk factors for early-

onset atherosclerosis in patients on haemodialysis.

Nephrology

(Carlton)

2005;

: 453–458. doi: 10.1111/j.1440-1797.2005.00475.x.

68. Shinkai S, Chaves PH, Fujiwara Y, Watanabe S, Shibata H, Yoshida

et al

. Beta2-microglobulin for risk stratification of total mortality

in the elderly population: comparison with cystatin C and C-reactive

protein.

Arch Intern Med

2008;

168

: 200–206. doi: 10.1001/archintern-

med.2007.64.

69. Kals J, Zagura M, Serg M, Kampus P, Zilmer K, Unt E,

et al

2-microglobulin, a novel biomarker of peripheral arterial disease,

independently predicts aortic stiffness in these patients.

Scand J Clin Lab

Invest

2011;

: 257–263. doi: 10.3109/00365513.2011.558108.

70. Joosten MM, Pai JK, Bertoia ML, Gansevoort RT, Bakker SJ, Cooke

JP,

et al.

2-microglobulin, cystatin C, and creatinine and risk of

symptomatic peripheral artery disease.

J Am Heart Assoc

2014;

. doi:

10.1161/JAHA.114.000803.

71. Ho DY, Cook NR, Britton KA, Kim E, Creager MA, Ridker PM,

et al.

High-molecular-weight and total adiponectin levels and inci-

dent symptomatic peripheral artery disease in women: a prospec-

tive investigation.

Circulation

2011;

124

: 2303–2311. doi: 10.1161/

CIRCULATIONAHA.111.045187.